On April 11, 2023 at 10:29:14 ET an unusually large
$269.34K block of Call contracts in Teva Pharmaceutical Industries
(TEVA) was bought,
with a strike price of $9.50 / share, expiring in 3 days (on April 14, 2023).
Fintel tracks all large options trades, and the premium spent on this trade was 5.02 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in TEVA options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 9,882.16% Downside
As of April 6, 2023,
the average one-year price target for Teva Pharmaceutical Industries is $-920.50.
The forecasts range from a low of $-911.48 to a high of $-947.57.
The average price target represents a decrease of 9,882.16% from its latest reported closing price of $9.41.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Teva Pharmaceutical Industries
is $15,827MM, an increase of 6.04%.
The projected annual non-GAAP EPS
is $2.60.
What is the Fund Sentiment?
There are 647 funds or institutions reporting positions in Teva Pharmaceutical Industries.
This is an increase
of
6
owner(s) or 0.94% in the last quarter.
Average portfolio weight of all funds dedicated to TEVA is 0.19%,
an increase
of 6.22%.
Total shares owned by institutions increased
in the last three months by 0.19% to 724,818K shares.
The put/call ratio of TEVA is 0.67, indicating a
bullish
outlook.
What are Large Shareholders Doing?
Capital Research Global Investors
holds 114,794K shares
representing 10.33% ownership of the company.
In it’s prior filing, the firm reported owning 117,190K shares, representing
a decrease
of 2.09%.
The firm
increased
its portfolio allocation in TEVA by 1.83% over the last quarter.
AGTHX – GROWTH FUND OF AMERICA
holds 58,735K shares
representing 5.29% ownership of the company.
In it’s prior filing, the firm reported owning 58,790K shares, representing
a decrease
of 0.09%.
The firm
decreased
its portfolio allocation in TEVA by 1.69% over the last quarter.
AIVSX – INVESTMENT CO OF AMERICA
holds 54,425K shares
representing 4.90% ownership of the company.
In it’s prior filing, the firm reported owning 56,796K shares, representing
a decrease
of 4.36%.
The firm
decreased
its portfolio allocation in TEVA by 1.12% over the last quarter.
Capital World Investors
holds 50,564K shares
representing 4.55% ownership of the company.
In it’s prior filing, the firm reported owning 39,330K shares, representing
an increase
of 22.22%.
The firm
increased
its portfolio allocation in TEVA by 37.95% over the last quarter.
Menora Mivtachim Holdings
holds 23,265K shares
representing 2.09% ownership of the company.
In it’s prior filing, the firm reported owning 23,308K shares, representing
a decrease
of 0.18%.
The firm
increased
its portfolio allocation in TEVA by 0.71% over the last quarter.
Teva- Pharmaceutical Industries Background Information
(This description is provided by the company.)
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
